Group 1 - The pharmaceutical and health industry in Beijing is accelerating towards becoming a globally influential modern pharmaceutical health industry cluster, with significant export growth in medical instruments and pharmaceuticals [1] - In the first eight months of this year, exports of medical instruments and pharmaceuticals reached 5.83 billion and 3.43 billion yuan, representing growth rates of 21.5% and 6.8% respectively [1] - The Beijing Economic-Technological Development Area hosts over 12,000 registered enterprises in the pharmaceutical sector, including more than 100 Fortune 500 companies and 17 unicorns [1] Group 2 - Biopharmaceutical companies are demanding an optimized cross-border R&D environment, particularly for the import and export of special items and biological materials [3] - The Yizhuang Customs has implemented intelligent approval processes for low-risk special items, improving overall export efficiency by approximately 40% [3] - The company has recorded over 75,000 intelligent product registrations, with intelligent approvals accounting for over 85% and approval efficiency improved by 65% [3] Group 3 - The Tianzhu Comprehensive Bonded Zone is a key import port for pharmaceuticals, with an expected import value of 96.04 billion yuan in 2024, including 92% of the national human vaccine imports [4] - The Tianzhu Customs has enhanced the efficiency of medical device imports, allowing for delivery to clients in as little as one hour [5] - The implementation of electronic smart access and IoT technology has significantly reduced customs clearance times for pharmaceuticals [5] Group 4 - The company has reported a 9% year-on-year increase in the scale of imported pharmaceutical products, reaching 27.7 billion yuan from January to August this year [7] - In the first eight months of 2025, the import of rare disease drugs in Beijing reached 2.66 billion yuan, a growth of 59.1%, with Tianzhu Comprehensive Bonded Zone accounting for 2.56 billion yuan, a growth of 78.3% [7]